



TEVA PHARMACEUTICAL INDUSTRIES LTD.

Contact: Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

George Barrett
President and CEO
Teva North America
(215) 591-3030

FOR IMMEDIATE RELEASE

Liraz Kalif / Kevin Mannix
Teva Investor Relations
(011) 972-3-926-7281 / (215) 591-8912

TEVA RECEIVES APPROVAL FOR GENERIC FOCALIN™ TABLETS

Jerusalem, Israel, January 30, 2007 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' Focalin™ (Dexmethylphenidate Hydrochloride) Tablets, 2.5 mg, 5 mg, and 10 mg. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

Teva's AB-rated Dexmethylphenidate HCl Tablets are indicated for the treatment of attention deficit hyperactivity disorder. The brand product had annual sales of approximately \$19 million for the twelve months ended September 2006, based on IMS sales data.

Teva is currently in patent litigation concerning this product in the U.S. District Court for the District of New Jersey.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate IVAX Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic product, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Wellbutrin XL® and the effects of competition on Copaxone® sales, including as a result of the reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities, environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.



30 בינואר, 2007

טבע מודיעה על קבלת אישור לגרסה הגנרית של טבליות Focalin™

טבע מודיעה כי קיבלה אישור סופי מרשות המזון והתרופות האמריקאית (FDA) לשיווק הגרסה הגנרית שלה לטבליות Focalin™ (Dexmethylphenidate Hydrochloride) של חברת Novartis, במינון של 2.5 מ"ג, 5 מ"ג ו-10 מ"ג. כחברה הראשונה אשר הגישה בקשה לאישור בהליך הידוע כ- paragraph IV למוצר זה, הוענקו לטבע 180 ימי בלעדיות בשיווק המוצר.

טבליות Dexmethylphenidate HCl של טבע מיועדות לטיפול בקשיי ריכוז והיפראקטיביות. המכירות השנתיות של המוצר המקורי היו כ- 19 מליון \$ בשנים-עשר החודשים שהסתיימו בספטמבר 2006, בהתבסס על נתוני IMS.

טבע נמצאת כעת בהתדיינות משפטית בנוגע לפטנט של המוצר בבית המשפט המחוזי של מחוז ניו ג'רזי, ארה"ב.

טבע תעשיות פרמצבטיות בע"מ הינה חברה גלובלית שבסיסה בישראל ואחת מ-20 החברות הפרמצבטיות המובילות בעולם. טבע, המתמחה בייצור תרופות גנריות וייחודיות, ייצור חומרים פעילים לתעשייה הפרמצבטית ומוצרים ווטרינרים, הינה החברה המובילה בעולם בתחום הגנריקה. לטבע אתרי ייצור, מחקר, שיווק והפצה בישראל, בצפון ובמרכז אמריקה ובאירופה. יותר מ-80% ממכירותיה של הקבוצה הן לצפון אמריקה ואירופה.

להלן הסעיף הידוע בארה"ב כ- Safe Harbor בנוסחו האנגלי ואשר מטרתו להגן על החברה, עפ"י הדין האמריקאי:

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic product, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities, environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.